ICAM1 and breast cancer: As can be seen from Table 4 (data are presented as median and ranges of values), in women after BC treatment level of NSE was 14.81 (12.75; 18.09), anti-NR-2 antibodies–0.45 (0.29; 0.76), ICAM-1–558.50 (510.50; 651.50), PECAM-1–104.15 (82.33; 128.75).